Activation of Vγ9Vδ2
T cells with butyrophilin
3A1
(BTN3A1) agonists such as (
E
)-4-hydroxy-3-methyl-but-2-enyl
diphosphate (HMBPP) has the potential to boost the immune response.
Because HMBPP is highly charged and metabolically unstable, prodrugs
may be needed to overcome these liabilities, but the prodrugs themselves
may be limited by slow payload release or low plasma stability. To
identify effective prodrug forms of a phosphonate agonist of BTN3A1,
we have prepared a set of diesters bearing one aryl and one acyloxymethyl
group. The compounds were evaluated for their ability to stimulate
Vγ9Vδ2 T cell proliferation, increase production of interferon
γ, resist plasma metabolism, and internalize into leukemia cells.
These bioassays have revealed that varied aryl and acyloxymethyl groups
can decouple plasma and cellular metabolism and have a significant
impact on bioactivity (>200-fold range) and stability (>10 fold
range),
including some with subnanomolar potency. Our findings increase the
understanding of the structure–activity relationships of mixed
aryl/acyloxymethyl phosphonate prodrugs.